John Simmons, MD
Neurology · Alamogordo, NMNPI 1841285962
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $482 of the $632 with a category attached, or 76.3%. 12 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 24.4% of the total. That places this record below the midpoint for neurology clinicians in NM, where the typical reported total is $623.
Across 27 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$154
- Harmony Biosciences LLC$116
- Novartis$101
- Pfizer$90
- Lilly USA, LLC$50
- Medtronic$22
- plus $98 from 6 others
What the payments were for
- Speaking & faculty fees$183%
- Food & beverage$48276%
- Education$13221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 6 | $154 |
| Harmony Biosciences LLC | 4 | $116 |
| Novartis | 5 | $101 |
| Pfizer | 1 | $90 |
| Lilly USA, LLC | 3 | $50 |
| Medtronic | 2 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
| Biogen | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
How this compares
$632 in reported general payments places this provider in the 50th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 20 | $330,177 |
| Emgality PenGalcanezumab-Gnlm | 21 | $27,867 |
| FingolimodFingolimod Hcl | 21 | $9,696 |
| Rufinamide | 12 | $9,175 |
| Clobazam | 18 | $7,015 |
| Oxcarbazepine | 109 | $6,924 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 90 | $4,400 |
| Gabapentin | 118 | $3,679 |
| Lacosamide | 31 | $3,606 |
| Levetiracetam | 69 | $3,319 |
| Primidone | 66 | $2,283 |
| Memantine Hcl | 49 | $1,922 |
| Modafinil | 25 | $1,768 |
| RizatriptanRizatriptan Benzoate | 67 | $1,373 |
| Baclofen | 65 | $1,288 |
Paid to pharmacies, not to this prescriber.
Other neurology in Alamogordo
- Karen LecomteAlamogordo$806
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Weiwei DaiRio Rancho$367K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.